Toll-like receptors (TLRs) are a group of ancient receptors found on the surface of cells in our innate immune system. They are responsible for detecting conserved molecules found on pathogenic microbes, called Pathogen Associated Molecular Patterns (PAMP), such as lipopolysaccharide (LPS) molecules on the cell surfaces of Gram-negative bacteria. The activation of TLRs leads to immune responses against the pathogen infection. Although the cell signalling follow the activation of TLRs is well characterized, the initial mechanisms for TLR activation upon detecting PAMPs are not well understood. For the TLR-2,-3 and-4 receptors, we reported that an enzyme called Neu1 sialidase forms a complex with the TLR receptors on the cell surface of naïve and activated macrophages (Amith et al, 2009). Activation of this Neu1 is induced by the binding of TLR ligands, such as LPS, to their respective receptors; a specific sialyl -2,3-linked β-galactosyl residue on the TLR is hydrolyzed by the activated Neu1 enzyme. Neuraminidase inhibitors such as BCX1827, DANA, zanamivir and oseltamivir carboxylate have a limited inhibition of this LPS-induced Neu1 activity in live macrophage cells. In contrast, Tamiflu (oseltamivir phosphate) completely blocked this Neu1 activity. Here, we tested the inhibitory potency of a series of DANA and modified Tamiflu derivatives against the activity of the Neu1 enzyme. The results suggest that the linear alkyl side chains of DANA derivatives may contribute to their increased inhibitory potency on LPS-induced Neu1 activity compared to the derivatives with methyl side chain branches and to the parent DANA compound.
Read full abstract